4.12
-0.04 (-0.96%)
| Penutupan Terdahulu | 4.16 |
| Buka | 4.17 |
| Jumlah Dagangan | 100,039 |
| Purata Dagangan (3B) | 657,430 |
| Modal Pasaran | 90,959,168 |
| Harga / Jualan (P/S) | 110.21 |
| Harga / Buku (P/B) | 0.930 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Nov 2025 |
| Margin Operasi (TTM) | -15,818.10% |
| EPS Cair (TTM) | -7.22 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 352.65% |
| Nisbah Semasa (MRQ) | 3.57 |
| Aliran Tunai Operasi (OCF TTM) | -111.99 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -76.86 M |
| Pulangan Atas Aset (ROA TTM) | -48.76% |
| Pulangan Atas Ekuiti (ROE TTM) | -144.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Adverum Biotechnologies, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.50 |
|
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.10% |
| % Dimiliki oleh Institusi | 79.44% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Principia Wealth Advisory, Llc | 30 Jun 2025 | 2,029,116 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 5.00 (HC Wainwright & Co., 21.36%) | Pegang |
| Median | 4.50 (9.22%) | |
| Rendah | 4.00 (RBC Capital, -2.91%) | Pegang |
| Purata | 4.50 (9.22%) | |
| Jumlah | 2 Pegang | |
| Harga Purata @ Panggilan | 4.27 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Nov 2025 | 5.00 (21.36%) | Pegang | 4.27 |
| 23 Sep 2025 | 30.00 (628.16%) | Beli | 4.06 | |
| RBC Capital | 28 Oct 2025 | 4.00 (-2.91%) | Pegang | 4.26 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |